Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24485042 | 1.00 | F11 (0.32) | F11F2FLT1FLT4KDR | |
| SCHEMBL24484321 | 0.95 | CNR2 (0.32) | F11F2CNR2 | |
| SCHEMBL29629843 | 0.95 | CNR2 (0.32) | F11F2CNR2 | |
| SCHEMBL24485045 | 0.94 | F11 (0.31) | F11F2FLT1FLT4KDR | |
| SCHEMBL29629797 | 0.94 | F11 (0.31) | F11F2FLT1FLT4KDR | |
| SCHEMBL24484370 | 0.86 | BTK (0.33) | F11F2FLT1FLT4KDR | |
| SCHEMBL24484958 | 0.85 | CNR2 (0.35) | F11F2CNR2 | |
| SCHEMBL29629758 | 0.84 | GABRA1 (0.32) | GABRA1LMNAHTT | |
| SCHEMBL24484858 | 0.84 | GABRA1 (0.32) | GABRA1LMNAHTT | |
| SCHEMBL31328346 | 0.84 | ANO1 (0.33) | F11F2FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | claimed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | claimed |
| EP-4251616-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven (BE) | 2023-10-04 | — | — | EP | claimed |
| WO-2022112352-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | claimed |
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-10-10 | — | — | US | disclosed |
| WO-2022112352-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | F11 4379/4885F2 4119/4885FLT1 4768/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | F11 4379/4885F2 4119/4885FLT1 4768/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | F11 3531/4885F2 2796/4885FLT1 4562/4885 |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | F11 4379/4885F2 4119/4885FLT1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.